Francisco J. Esteva: Genetic testing and tumor genetic profiling serve different but complementary roles in cancer care
Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital and a Professor of Medicine at the Zucker School of Medicine, shared a post on LinkedIn:
“Genetic testing and tumor genetic profiling serve different but complementary roles in cancer care.
Genetic testing in healthy individuals looks for inherited mutations – like BRCA1 or BRCA2 – that increase cancer risk. This information can guide preventive steps, including enhanced screening or risk-reducing surgery.
In contrast, tumor genetic profiling examines mutations within the cancer itself, identifying molecular targets for treatment. For instance, if a person with a BRCA mutation develops breast cancer, that same mutation can inform the use of therapies such as PARP inhibitors.
Understanding both germline and somatic mutations allows for truly personalized care – improving outcomes and empowering patients with knowledge at every stage.”
Proceed to the video attached to the post.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023